Peptide Mixture for Lyme Disease Antibody Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Lyme disease diagnostic assays, such as the C6 peptide assay, are not sufficiently sensitive for detecting certain strains of infectious Borrelia, leading to a need for improved methods to detect Borrelia antigens and serodiagnosis.
Innovation Solution
A mixture of isolated peptides with specific sequences, including an N-terminal and C-terminal peptide sequence, is used to bind to antibodies recognizing Borrelia antigens, enhancing the detection of antibodies against a wide range of Borrelia species, including those not detected by existing assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If the C6 peptide assay is used for Lyme disease diagnosis, then the sensitivity for disseminated and late Lyme disease is improved, but the sensitivity for certain strains of infectious Borrelia is insufficient
Solution Approach 1:
The patent combines multiple distinct peptide antigens (C6 peptide from VlsE protein, Irp6 peptide from outer surface protein, and VlsE peptide from variable surface antigen) into a single multiplex assay system. This merging of multiple antigen targets allows the assay to detect antibodies against different Borrelia species and strains simultaneously, resolving the contradiction by maintaining high sensitivity for disseminated Lyme disease while expanding detection coverage to include strains missed by the C6 peptide alone.
Solution Approach 2:
The assay system is designed with multi-functional peptide antigens that can recognize antibodies against multiple Borrelia species (Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, and other European strains). The combination of C6, Irp6, and VlsE peptides creates a universal detection system that maintains the high sensitivity of C6 for late-stage disease while adding functionality to detect diverse Borrelia strains through the additional peptide targets.
2Measurement precision
If whole-cell Borrelia burgdorferi antigen or recombinant Borrelia proteins are used in first tier assays, then the assay can detect Borrelia antibodies, but the assay becomes difficult to interpret and is complicated by Borrelia antibodies arising from vaccination rather than infection
Solution Approach 1:
The patent extracts and utilizes only the specific antigenic peptide sequences (C6, Irp6, and VlsE) that are responsible for antibody binding, rather than using whole-cell antigens or full recombinant proteins. By isolating these critical peptide epitopes and presenting them in a controlled multiplex format, the assay maintains detection capability while eliminating the interpretational complexity and cross-reactivity issues associated with whole-cell antigens and vaccination-induced antibodies.
Solution Approach 2:
The assay employs distinct, well-characterized peptide antigens with known specificities (C6 from VlsE, Irp6 from outer surface protein, VlsE from variable surface antigen) rather than heterogeneous whole-cell antigens. Each peptide has defined local antigenic properties that enable specific antibody recognition, improving interpretability by allowing clear distinction between infection-specific antibodies and those from vaccination, while maintaining detection capability through the combined peptide panel.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide mixture provides robust detection of antibody responses to Borrelia antigens, improving the sensitivity and accuracy of Lyme disease diagnosis, particularly for strains missed by traditional assays.
Implementation Method 1
A mixture of isolated peptides with specific sequences, including an N-terminal and C-terminal peptide sequence, is used to bind to antibodies recognizing Borrelia antigens
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to Borrelia antigens are disclosed. The peptide compositions comprise polypeptide sequences comprising variants in the IR6 domain of the Borrelia VIsE protein. Also provided are devices, methods, and kits comprising such peptide compositions and useful for the detection of antibodies that bind to Borrelia antigens and the diagnosis of Lyme disease.